U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib) roche.com ↗
2020-08-03
Roche Global Development
Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer roche.com ↗
2020-05-29
Roche Global Development
CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer roche.com ↗
2019-08-16
Roche Global Development
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours roche.com ↗
2019-06-18
Roche Global Development
Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek roche.com ↗
2019-05-16
Roche Global Development
Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents roche.com ↗
2019-02-19
Roche Global Development
FDA grants Priority Review to Roche's personalised medicine entrectinib roche.com ↗
2018-10-21
Roche Global Development
Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours roche.com ↗
2018-09-24
Roche Global Development
Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer roche.com ↗
Evidence & citations 12 cited values
Every value below carries the sentence it was read from.
38 sources stand behind the page.
Field
Value
Cited text
Known as
entrectinib
“entrectinib used outside of indication, based on biomarker” NCT04817956 ↗34
“entrectinib 600 mg orally once daily” NCT06145308 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1983268 ↗
Known as
Rozlytrek
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1983268 ↗
Known as
RXDX-101
“Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3),...” NCT02097810 ↗
Action
Inhibit
“Entrectinib (RXDX-101) is an orally available inhibitor” NCT02097810 ↗
Modality
Small molecule
“Entrectinib (RXDX-101) is an orally available tyrosine kinase inhibitor, including TrkA.” PMID 26565381 ↗Dec 2015
Route
Oral
“received entrectinib orally at a dose of at least 600 mg once per day” PMID 31838007 ↗Dec 2019
Target
ALK
“Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3),...” NCT02097810 ↗
Target
NTRK1
“Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3),...” NCT02097810 ↗
Target
NTRK2
“Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3),...” NCT02097810 ↗
Target
NTRK3
“Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3),...” NCT02097810 ↗
Target
ROS1
“Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3),...” NCT02097810 ↗